Effective of Early Treatment of Insomnia on the Adherence of CPAP
NCT07556432, Not applicable, Not yet recruiting, Centre Hospitalier Universitaire Vaudois
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effective of Early Treatment of Insomnia on the Adherence of CPAP | ClinicalTrials.gov |
| NCT number | NCT07556432 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Centre Hospitalier Universitaire Vaudois | ClinicalTrials.gov |
| Conditions | Obstructive Sleep Apnea (OSA), Insomnia Chronic | ClinicalTrials.gov |
| Interventions | digital CBT-I, CPAP | ClinicalTrials.gov |
| First posted | 2026-04-29 | ClinicalTrials.gov |
| Last updated | 2026-04-29 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | CPAP adherence | 6 months | mean hours of CPAP use over the prior three months | ClinicalTrials.gov |
| Secondary | Change in ambulatory heart rate | Baseline to 6 months | Measured using 24-hour ambulatory blood pressure monitoring (millimeters of mercury, mmHg). Mean systolic blood pressure over 24 hours will be calculated. Lower values indicate better cardiovascular status. | ClinicalTrials.gov |
| Secondary | Change in ambulatory systolic blood pressure | Baseline to 6 months | Measured using 24-hour ambulatory blood pressure monitoring (millimeters of mercury, mmHg). Mean systolic blood pressure over 24 hours will be calculated. Lower values indicate better cardiovascular status | ClinicalTrials.gov |
| Secondary | Change in ambulatory diastolic blood pressure | Baseline to 6 months | Measured using 24-hour ambulatory blood pressure monitoring (millimeters of mercury, mmHg). Mean diastolic blood pressure over 24 hours will be calculated. Lower values indicate better cardiovascular status. | ClinicalTrials.gov |
| Secondary | Change in cognitive performance assessed by the Montreal Cognitive Assessment | Baseline to 6 months | Measured using the Montreal Cognitive Assessment (MoCA), a 30-point cognitive screening tool assessing multiple cognitive domains. Scores range from 0 to 30, with higher scores indicating better cognitive performance. | ClinicalTrials.gov |
| Secondary | Change in processing speed assessed by the Trail Making Test | Baseline to 6 months | Measured using the Trail Making Test. Outcome is completion time in seconds. Lower values indicate better performance. | ClinicalTrials.gov |
| Secondary | Change in executive function assessed by the Stroop Color-Word Test | Baseline to 6 months | Measured using the Stroop Color-Word Test. Outcome is completion time or interference score (in seconds or derived score depending on version). Lower values indicate better cognitive performance (reduced interference). | ClinicalTrials.gov |
| Secondary | Change in verbal fluency | Baseline to 6 months | Measured using a phonemic (e.g., letter fluency) and semantic (e.g., animal naming) verbal fluency task. Outcome is the number of correct words generated in 60 seconds. Higher values indicate better performance. | ClinicalTrials.gov |
| Secondary | Change in episodic memory assessed by the Free and Cued Selective Reminding Test | Baseline to 6 months | Measured using the Free and Cued Selective Reminding Test (FCSRT). Outcomes include free recall and total recall scores. Scores typically range from 0 to 48, with higher scores indicating better memory performance. | ClinicalTrials.gov |
| Secondary | Change in subjective cognitive complaints assessed by the Cognitive Failures Questionnaire | Baseline to 6 months | Measured using the Cognitive Failures Questionnaire (CFQ-2.0). Scores range from 0 to 100, with higher scores indicating greater cognitive complaints (worse outcome). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)